Earnings Release: Here's Why Analysts Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$12.71
Analysts Offer Insights on Healthcare Companies: Certara (CERT), Exact Sciences (EXAS) and AbCellera Biologics (ABCL)
AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2024 Earnings Call Transcript
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript
Analysts Are Bullish on These Healthcare Stocks: ICU Medical (ICUI), AbCellera Biologics (ABCL)
Q1 2024 Abcellera Biologics Inc Earnings Call Transcript
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
AbCellera Biologics Inc (ABCL) Q1 2024 Earnings: Misses Revenue and Net Loss Estimates
AbCellera Biologics Inc (ABCL) Q1 2024 Earnings: Misses Revenue and Net Loss Estimates
AbCellera Reports Q1 2024 Business Results
Insider Stock Buying Reaches US$1.61m On AbCellera Biologics
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.